Literature DB >> 7658357

Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose.

C G Sahajwalla1, E D Helton, E D Purich, C L Hoppel, B E Cabana.   

Abstract

L-Carnitine, a naturally occurring compound, is indicated in the treatment of primary systemic carnitine deficiency. To assess the differences in pharmacokinetic parameters calculated from data corrected for baseline versus those from "uncorrected" data, compartmental fitting was carried out for baseline corrected and original plasma concentration data obtained following a single intravenous (iv) dose of 20 mg/kg. For free L-carnitine, mean volumes of distribution at steady state (Vdss) of the central compartment were similar using either approach (9.86 versus 11.2 L). However, Vdss (54.0 versus 29.0 L) and apparent elimination half-life (17.4 versus 5.0 h) were significantly different between the two data bases. Similar observations were noted for pharmacokinetic parameters based on plasma concentrations of total L-carnitine. Although the pharmacokinetic parameters obtained after baseline correction may represent the kinetics of a bolus dose, the pharmacokinetic parameters from uncorrected plasma data probably represent the clinical settings for patients. Baseline correction also probably has its greatest value in attempting to determine and/or define the biological half-life and Vdss for the "exogenously" administered dose and uncorrected data best describes the pharmacokinetics of composite endogenous and exogenous L-carnitine levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658357     DOI: 10.1002/jps.2600840521

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

2.  Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption.

Authors:  S Pace; A Longo; S Toon; P Rolan; A M Evans
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 3.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Significance of Levocarnitine Treatment in Dialysis Patients.

Authors:  Hiroyuki Takashima; Takashi Maruyama; Masanori Abe
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

5.  Septic Shock Nonsurvivors Have Persistently Elevated Acylcarnitines Following Carnitine Supplementation.

Authors:  Michael A Puskarich; Charles R Evans; Alla Karnovsky; Arun K Das; Alan E Jones; Kathleen A Stringer
Journal:  Shock       Date:  2018-04       Impact factor: 3.454

6.  Regulation of Genes Involved in Carnitine Homeostasis by PPARα across Different Species (Rat, Mouse, Pig, Cattle, Chicken, and Human).

Authors:  Robert Ringseis; Gaiping Wen; Klaus Eder
Journal:  PPAR Res       Date:  2012-10-23       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.